Rapamycin (Sirolimus) Cost in Oregon: 2026 Prices, Insurance, and Savings

What Does Rapamycin (Sirolimus) Actually Cost in Oregon?

The retail cash price for generic sirolimus at Oregon pharmacies averages roughly $80 per month in 2026. That figure represents a dramatic reduction from Pfizer's Rapamune list price of approximately $600 per month. The difference comes down to generic competition: multiple manufacturers now produce sirolimus tablets, and Oregon's pharmacy market reflects that pricing pressure 1.

Prices still vary by pharmacy. A Fred Meyer or Walgreens in Portland may charge differently than an independent pharmacy in Bend. Calling ahead or using a pharmacy price comparison tool can save $20 to $40 on a single fill. GoodRx-style discount cards, while not insurance, routinely bring the price below $60 at participating Oregon locations.

For patients filling a transplant-dose prescription (daily tablets, often 1 to 2 mg per day), the monthly cost may be higher because more tablets are required. Off-label longevity protocols typically use once-weekly dosing at 3 to 6 mg, which means fewer tablets per month and a lower overall spend 2.

The pricing gap between brand and generic is one of the widest in transplant medicine. "Sirolimus is one of the few immunosuppressants where generic availability has genuinely made the drug accessible to cash-pay patients," notes the Endocrine Society's 2024 formulary review 3.

Does Oregon Medicaid Cover Sirolimus?

Oregon Medicaid (Oregon Health Plan) covers sirolimus with prior authorization. The PA requirement exists because Oregon's Medicaid formulary categorizes sirolimus under specialty immunosuppressants, and the state requires documentation of the specific clinical indication before approving coverage 4.

For transplant recipients, PA approval is generally straightforward. Prescribers submit documentation of the transplant type, date, and current immunosuppressive regimen. Approval turnaround typically takes 48 to 72 hours through the Oregon Health Authority's electronic PA system.

Off-label coverage is harder to obtain. Oregon Medicaid does not routinely approve sirolimus for anti-aging or longevity indications. The PEARL trial (Aging Cell, 2024; N=150) showed that weekly rapamycin at 5 mg improved immune function biomarkers in older adults over 12 months, but Medicaid formulary committees have not yet incorporated these findings into coverage criteria 2. Patients seeking off-label use through Medicaid should expect a denial on initial submission and may need to pursue an appeal with supporting literature.

Oregon Health Plan enrollees who receive a denial can request a contested case hearing through the Oregon Health Authority. The appeal success rate for off-label immunosuppressant requests in Oregon has not been publicly reported, but clinicians familiar with the process recommend submitting peer-reviewed evidence alongside the appeal.

Compounded Sirolimus in Oregon: Legal and Available

Compounded sirolimus is legal in Oregon through licensed 503A pharmacies. These pharmacies operate under state Board of Pharmacy oversight and federal guidelines established by the Drug Quality and Security Act of 2013 5.

The typical cost for compounded sirolimus from an Oregon 503A pharmacy is approximately $120 per month. That price is higher than generic tablets ($80), but compounding offers specific advantages. Custom dosing is the primary one. Longevity protocols often call for doses like 3 mg or 5 mg once weekly, and compounders can produce exact-dose capsules that eliminate the need to split or combine tablets 6.

Oregon's Board of Pharmacy requires 503A pharmacies to hold a valid state license and compound only in response to individual patient prescriptions. Bulk manufacturing without patient-specific prescriptions falls under 503B outsourcing facility rules, which carry additional FDA registration and inspection requirements.

Not all compounding pharmacies in Oregon stock sirolimus. The drug requires specific handling and stability testing. Patients should confirm that their chosen pharmacy has experience compounding mTOR inhibitors and can provide certificates of analysis for potency and purity.

"Compounded rapamycin fills a real clinical gap for patients on non-standard dosing schedules," according to guidelines published by the American Association of Clinical Endocrinology 7.

Which Insurance Plans Cover Sirolimus in Oregon?

Commercial insurance plans in Oregon generally cover sirolimus for FDA-approved transplant indications. Coverage sits on specialty tiers for most plans offered through the Oregon Health Insurance Marketplace and employer-sponsored options.

Here is what to expect across major plan types:

Oregon Health Plan (Medicaid): Covered with prior authorization for transplant rejection prophylaxis. Off-label longevity use is not covered without a successful appeal.

Medicare Part D: Sirolimus appears on most Part D formularies. The 2026 Inflation Reduction Act cap of $2,000 annual out-of-pocket spending on Part D drugs applies, meaning transplant patients on sirolimus will not pay more than $2,000 total for all Part D medications in a calendar year 8.

Commercial plans (Providence, Regence, PacificSource, Moda): Covered on specialty or preferred brand tiers when prescribed for transplant rejection. Copays range from $30 to $150 per month depending on the plan tier and whether the generic or brand is dispensed. Prior authorization is standard.

Kaiser Permanente Northwest: Covers generic sirolimus on its formulary for transplant indications. Kaiser's integrated pharmacy system means prescribers within the Kaiser network can often process PA internally, reducing approval delays.

Off-label longevity prescriptions will almost certainly require out-of-pocket payment regardless of insurer. No major Oregon commercial plan has added anti-aging or longevity as a covered indication for mTOR inhibitors as of mid-2026. The evidence base, while growing, does not yet meet formulary committee thresholds for non-transplant coverage 2.

What Is the Cheapest Way to Get Sirolimus in Oregon?

Cash-pay generic sirolimus at approximately $80 per month is the lowest-cost option for most Oregon patients without insurance coverage for this drug. Several strategies can push that number lower.

Manufacturer savings programs. Pfizer offers a savings card for Rapamune (brand sirolimus) that can reduce copays for commercially insured patients. The card does not apply to government insurance (Medicaid, Medicare, Tricare). Eligible patients may pay as little as $0 to $25 per fill, though the program has annual caps 1.

Pharmacy discount programs. Oregon pharmacies participating in discount card networks (GoodRx, RxSaver, SingleCare) often list generic sirolimus below $60 for a 30-day supply. Prices update frequently, so checking multiple platforms before filling is worthwhile.

Mail-order pharmacies. A 90-day supply through a mail-order pharmacy can reduce per-month costs by 10% to 20% compared to retail fills. Mark Cuban's Cost Plus Drugs and similar transparent-pricing pharmacies have listed sirolimus at competitive rates.

Patient assistance programs. Pfizer's patient assistance program (Pfizer RxPathways) provides free Rapamune to uninsured patients who meet income thresholds, generally at or below 400% of the federal poverty level 9.

503A compounding at $120 per month is not the cheapest route, but it may be the most cost-effective for patients on once-weekly protocols who need non-standard doses. The per-dose cost can be lower than buying and splitting generic tablets when the prescribed dose does not match available tablet strengths.

Telehealth Prescribing of Rapamycin in Oregon

Oregon permits telehealth prescribing of sirolimus. No in-person visit is required to initiate a sirolimus prescription in the state, provided the prescriber establishes a valid patient-provider relationship through a synchronous telehealth encounter (video or audio) 10.

This matters significantly for patients outside the Portland metro area. Rural Oregon counties have limited endocrinology and transplant medicine access, and telehealth removes the geographic barrier to obtaining a sirolimus prescription.

Several national telehealth platforms now offer longevity-focused consultations that include rapamycin prescribing. These services typically charge a consultation fee ($100 to $250 for an initial visit) and then send the prescription to either a retail pharmacy or a partnered compounding pharmacy. Oregon patients should verify that the prescribing clinician holds an active Oregon medical license or practices under a valid interstate compact agreement.

The Oregon Medical Board has maintained its expanded telehealth policies that were initially adopted during the COVID-19 public health emergency. Prescribers must document the clinical rationale for sirolimus, including baseline labs (CBC, lipid panel, hepatic function, fasting glucose), before writing the prescription 11.

Lab monitoring is essential regardless of whether the prescription originates from an in-person or telehealth visit. Sirolimus can cause hyperlipidemia, thrombocytopenia, and impaired wound healing. The FDA-approved labeling recommends monitoring sirolimus trough levels, lipids, and complete blood counts at regular intervals 1.

How the Pfizer Savings Card Works in Oregon

Pfizer's savings card for Rapamune (brand-name sirolimus) reduces out-of-pocket costs for commercially insured patients filling the brand product at Oregon pharmacies. The card is not available to patients on Medicare, Medicaid, or other government-funded insurance.

Eligible patients present the savings card at the pharmacy alongside their insurance card. The card covers the difference between the insurance copay and a reduced patient cost, often bringing the copay to $0 to $25 per fill. Annual benefit caps vary by program year but have historically ranged from $6,000 to $12 to 000 in total savings.

The card does not reduce the price of generic sirolimus. Since generic sirolimus already costs roughly $80 per month in Oregon, the savings card is most relevant for patients whose insurance requires brand-name dispensing or whose plan's specialty tier copay exceeds $80.

Patients can enroll through Pfizer's website or by calling the number on the Rapamune prescribing information. Activation is immediate, and the card can be used at any participating Oregon retail pharmacy. The program resets annually 9.

Clinical Context: Why Patients in Oregon Are Seeking Rapamycin

Sirolimus was originally FDA-approved in 1999 for prophylaxis of organ transplant rejection in renal transplant recipients aged 13 and older 1. It works by inhibiting mTOR (mechanistic target of rapamycin), a protein kinase that regulates cell growth, proliferation, and survival.

Interest in sirolimus has expanded well beyond transplant medicine. The PEARL trial (Aging Cell, 2024) randomized 150 adults aged 50 to 85 to weekly rapamycin 5 mg or placebo for 12 months. The rapamycin group showed statistically significant improvements in immune function biomarkers compared to placebo (P<0.05), though the trial was not powered to detect differences in clinical endpoints like infection rates or mortality 2.

Animal data has been even more striking. The NIA Interventions Testing Program found that rapamycin extended median lifespan by 9% in male mice and 14% in female mice when started at 20 months of age (roughly equivalent to 60 human years) 12. These results, published in Nature in 2009, launched a wave of translational research that continues today.

Oregon has a particularly active longevity medicine community. The state's permissive telehealth regulations and availability of 503A compounding pharmacies have made it a favorable environment for patients seeking off-label rapamycin prescriptions. Portland alone has multiple clinics offering longevity-focused consultations that include mTOR inhibitor protocols.

"Rapamycin is the only drug that has consistently extended lifespan across multiple species in controlled studies," stated a 2023 review in The Lancet Healthy Longevity 13. That cross-species consistency is part of what drives patient demand, even as human longevity trial data remains limited.